Home > Result Summaries: Compounds > Human Papillomavirus Types 16 and 18 Vaccine > Result Summary for 110659

Result Summary for 110659

Result Summary

Protocol ID:	110659
Clinical Study ID:	110659
Official Title:	Evaluation of the safety and immunogenicity of GSK Bio's HPV vaccine 580299 when administered in healthy females aged 9 - 25 years using an alternative schedule and an alternative dosing as compared to the standard schedule and dosing
Phase:	phase 1
Study Indications or Diseases:	Infections, Papillomavirus
Generic Name:	Human Papillomavirus Types 16 and 18 Vaccine
Trade/Product Name:	Cervarix
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Romanowski B et al. Immunogenicity/efficacy over 9.4 years and immunogenicity after 2 doses. Abstract presented at the Public Health Association of Australia (PHAA), Darwin, Australia. 19-21 June 2012. Romanowski B. et al. Immune response to the HPV-16/18 AS04-adjuvantedvaccine administered as a 2-dose or 3-dose schedule 2 years after vaccination. Abstract presented at European Research Organization on Genital Infection and Neoplasia 2011 (EUROGIN). Lisbon, Portugal, 8-11 May 2011. Schwarz TF et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule upto 3 years after vaccination. Abstract presented at the 20th World Congress of Gynecology & Obstetrics (FIGO), Rome, Italy, 7-12 October 2012. Romanowski B et al. (2011) Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 7(12):1374-1386. Romanowski B et al. HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the standard 3-dose schedule. Abstract presented at European Research Organization on Genital Infection and Neoplasia 2010 (EUROGIN). Monte Carlo, Monaco, 17-20 February 2010.